Search Videos and More

Showing 25 - 36 of 116 results

Previous| 1... 2 | 3 | 4 ...10 |Next


Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome Video

Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome

New research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.
Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting News

Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting

In this exclusive MedPage Today video, ESMO Scientific Co-Chair Pasi A. Jänne, MD, PhD, director of the Chen-Huang Center for EGFR-Mutant Lung Cancer at Dana-Farber Cancer Institute in Boston, highlights some of the important lung cancer abstracts from the conference.
Treatment for Adults with Acute Lymphoblastic Leukemia Video

Treatment for Adults with Acute Lymphoblastic Leukemia

Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.
New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life News

New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber Brigham Cancer Center.
Newsweek Names Dana-Farber #3 in the World for Cancer News

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
Breast Cancer Research at ESMO Video

Breast Cancer Research at ESMO

Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
Lung Cancer Research at ESMO Video

Lung Cancer Research at ESMO

Dana-Farber's Pasi A. Jänne, MD, PhD, provides insight on DESTINY-Lung01 trial in lung cancer highlighted at ESMO 2021.
Bladder Cancer Research at ESMO Video

Bladder Cancer Research at ESMO

Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.
Kidney Cancer Research at ESMO Video

Kidney Cancer Research at ESMO

Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds News

Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds

A combination of two immunotherapy drugs, already shown to be more effective in patients with advanced melanoma than one of the drugs alone, also prolongs the benefit to patients who receive subsequent therapies, a clinical trial led by Dana-Farber Cancer Institute investigators indicates. The findings will be presented today at the 2021 Congress of the European Society of Medical Oncology (ESMO).
Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene News

Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene

More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
Researchers Set Sights on New Ovarian Cancer Treatment Strategies News

Researchers Set Sights on New Ovarian Cancer Treatment Strategies

Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes.

Showing 25 - 36 of 116 results

Previous| 1... 2 | 3 | 4 ...10 |Next